Patricio A. Pazmiño, MD, PhD
Potential Conflicts of Interest: None disclosed.
Pazmiño P.; Adverse Effects of Dabigatran. Ann Intern Med. 2012;157:916. doi: 10.7326/0003-4819-157-12-201212180-00016
Download citation file:
Published: Ann Intern Med. 2012;157(12):916.
TO THE EDITOR:
I read Radecki's article (1) with interest and agree with his concerns. Some of the potential harms stem from dabigatran's use for unapproved indications and in populations that have not been well-studied. The approval of dabigatran in the United States was based mostly on the results of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial involving more than 18 000 patients (2). Unfortunately, this trial did not include patients with creatinine clearances less than 30 mL/min per 1.73 m2, which is common in the elderly and in patients with stage 4 or 5 chronic kidney disease.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only